Information

Related Research Units

Hematology and Oncology Research
Springer Laboratory Research
PCMM Research

Research Overview

Timothy A. Springer discovered with monoclonal antibodies, then cloned and functionally and structurally characterized, many of the adhesion receptors in the immune system. He was the first to demonstrate that lymphocytes and leukocytes had adhesion molecules. His work on these receptors has advanced to characterizing their interactions and allosteric transitions by x-ray crystallography, electron microscopy, and laser tweezers force spectroscopy. His discoveries directly led to the development and FDA approval of Efalizumab, an antibody to LFA-1, and Alefacept, an LFA-3 Fc fusion, both for plaque psoriasis.

Dr. Springer later discovered the three-step paradigm for leukocyte diapedesis: 1) rolling adhesion of leukocytes on the vessel wall through selectins; 2) activation of G protein-coupled receptors on the leukocyte by chemoattractants; and 3) activation of integrin adhesiveness for CAMs on endothelium, which mediates firm adhesion and diapedesis. These discoveries led him to found LeukoSite in 1993. LeukoSite developed three FDA approved therapeutics, including vedolizumab (Entyvio), an antibody to integrin alpha4 beta7 approved for moderate to severe ulcerative colitis and Crohn's disease in 2014. LeukoSite was acquired in 1999 by Millennium Pharmaceuticals.

Dr. Springer’s academic interests now focus on how protein conformational change together with tensile force activates integrins, von Willebrand factor, the transforming growth factor-beta family, and adhesins on malaria sporozoites, and discovering new binding partners. Currently, he is a successful private investor in biotech with seats on five corporate and two non-profit boards. His newest endeavor is the Institute for Protein Innovation, a non-profit to advance entrepreneurship and innovation in protein therapeutics and open-source antibodies and small molecules.

Research Background

Timothy A. Springer is Professor of Biological Chemistry and Molecular Pharmacology at Harvard Medical School and the Program of Cellular and Molecular Medicine at Boston Children’s Hospital. Dr. Springer graduated from the University of California, Berkeley, and earned a Ph.D. in molecular biology and biochemistry from Harvard University. He is a member of the National Academy of Sciences and the American Academy of Arts and Sciences. In 2004, he was co-recipient of the prestigious Crafoord Prize given by the Royal Swedish Academy of Sciences. Dr. Springer is the recipient of the 2019 Canada Gairdner International Award, recognizing his “seminal discoveries and major scientific contributions constitut[ing] an original and significant achievement in biomedical science.”

Dr. Springer was the 2022 recipient of the Lasker Basic Medical Research Award and was elected to the National Academy of Medicine in 2023.

Media

On Answers

Tim Springer, PhD, winner of the 2022 Lasker Basic Medical Research Award

Publications

  1. De Novo Design of Integrin a5ß1 Modulating Proteins for Regenerative Medicine. bioRxiv. 2024 Jul 10. View Abstract
  2. Synthetic integrin antibodies discovered by yeast display reveal aV subunit pairing preferences with ß subunits. MAbs. 2024 Jan-Dec; 16(1):2365891. View Abstract
  3. Ligand binding initiates single-molecule integrin conformational activation. Cell. 2024 Jun 06; 187(12):2990-3005.e17. View Abstract
  4. Synthetic integrin antibodies discovered by yeast display reveal aV subunit pairing preferences with ß subunits. bioRxiv. 2024 Jan 27. View Abstract
  5. De novo design of highly selective miniprotein inhibitors of integrins avß6 and avß8. Nat Commun. 2023 09 13; 14(1):5660. View Abstract
  6. Structural insights into MIC2 recognition by MIC2-associated protein in Toxoplasma gondii. Commun Biol. 2023 08 31; 6(1):895. View Abstract
  7. De novo design of highly selective miniprotein inhibitors of integrins avß6 and avß8. bioRxiv. 2023 Jun 12. View Abstract
  8. Conformational change of Plasmodium TRAP is essential for sporozoite migration and transmission. EMBO Rep. 2023 Jul 05; 24(7):e57064. View Abstract
  9. A recombinant technique for mapping functional sites of heterotrimeric collagen helices: Collagen IV CB3 fragment as a prototype for integrin binding. J Biol Chem. 2023 07; 299(7):104901. View Abstract
  10. A specialized integrin-binding motif enables proTGF-ß2 activation by integrin aVß6 but not aVß8. Proc Natl Acad Sci U S A. 2023 06 13; 120(24):e2304874120. View Abstract
  11. Conformation of von Willebrand factor in shear flow revealed with stroboscopic single-molecule imaging. Blood. 2022 12 08; 140(23):2490-2499. View Abstract
  12. Single-molecule characterization of subtype-specific ß1 integrin mechanics. Nat Commun. 2022 12 03; 13(1):7471. View Abstract
  13. Reflections on Integrins-Past, Present, and Future: The Albert Lasker Basic Medical Research Award. JAMA. 2022 10 04; 328(13):1291-1292. View Abstract
  14. Structures of VWF tubules before and after concatemerization reveal a mechanism of disulfide bond exchange. Blood. 2022 09 22; 140(12):1419-1430. View Abstract
  15. A general chemical principle for creating closure-stabilizing integrin inhibitors. Cell. 2022 09 15; 185(19):3533-3550.e27. View Abstract
  16. Dynamics of integrin a5ß1, fibronectin, and their complex reveal sites of interaction and conformational change. J Biol Chem. 2022 09; 298(9):102323. View Abstract
  17. Monomeric prefusion structure of an extremophile gamete fusogen and stepwise formation of the postfusion trimeric state. Nat Commun. 2022 07 13; 13(1):4064. View Abstract
  18. Von Willebrand factor A1 domain stability and affinity for GPIba are differentially regulated by its O-glycosylated N- and C-linker. Elife. 2022 05 09; 11. View Abstract
  19. Loss of LRRC33-Dependent TGFß1 Activation Enhances Antitumor Immunity and Checkpoint Blockade Therapy. Cancer Immunol Res. 2022 04 01; 10(4):453-467. View Abstract
  20. Regulation of integrin a5ß1 conformational states and intrinsic affinities by metal ions and the ADMIDAS. Mol Biol Cell. 2022 05 15; 33(6):ar56. View Abstract
  21. Protection of the Prodomain a1-Helix Correlates with Latency in the Transforming Growth Factor-ß Family. J Mol Biol. 2022 03 15; 434(5):167439. View Abstract
  22. Structural basis of malaria transmission blockade by a monoclonal antibody to gamete fusogen HAP2. Elife. 2021 12 23; 10. View Abstract
  23. Single-molecule imaging of von Willebrand factor reveals tension-dependent self-association. Blood. 2021 12 09; 138(23):2425-2434. View Abstract
  24. Low-affinity integrin states have faster ligand-binding kinetics than the high-affinity state. Elife. 2021 12 02; 10. View Abstract
  25. Complement Receptor 3 Forms a Compact High-Affinity Complex with iC3b. J Immunol. 2021 06 15; 206(12):3032-3042. View Abstract
  26. Disulfide exchange in multimerization of von Willebrand factor and gel-forming mucins. Blood. 2021 03 04; 137(9):1263-1267. View Abstract
  27. CD11c regulates hematopoietic stem and progenitor cells under stress. Blood Adv. 2020 12 22; 4(24):6086-6097. View Abstract
  28. Evolutionarily distant I domains can functionally replace the essential ligand-binding domain of Plasmodium TRAP. Elife. 2020 07 10; 9. View Abstract
  29. Design and assessment of TRAP-CSP fusion antigens as effective malaria vaccines. PLoS One. 2020; 15(1):e0216260. View Abstract
  30. General structural features that regulate integrin affinity revealed by atypical aVß8. Nat Commun. 2019 12 02; 10(1):5481. View Abstract
  31. Specific high affinity interaction of Helicobacter pylori CagL with integrin aV ß6 promotes type IV secretion of CagA into human cells. FEBS J. 2019 10; 286(20):3980-3997. View Abstract
  32. Electrostatic Steering Enables Flow-Activated Von Willebrand Factor to Bind Platelet Glycoprotein, Revealed by Single-Molecule Stretching and Imaging. J Mol Biol. 2019 03 29; 431(7):1380-1396. View Abstract
  33. The von Willebrand factor D'D3 assembly and structural principles for factor VIII binding and concatemer biogenesis. Blood. 2019 04 04; 133(14):1523-1533. View Abstract
  34. A Tandem Mass Spectrometry Sequence Database Search Method for Identification of O-Fucosylated Proteins by Mass Spectrometry. J Proteome Res. 2019 02 01; 18(2):652-663. View Abstract
  35. Fusion surface structure, function, and dynamics of gamete fusogen HAP2. Elife. 2018 10 03; 7. View Abstract
  36. A Milieu Molecule for TGF-ß Required for Microglia Function in the Nervous System. Cell. 2018 06 28; 174(1):156-171.e16. View Abstract
  37. Ligand- and cation-induced structural alterations of the leukocyte integrin LFA-1. J Biol Chem. 2018 04 27; 293(17):6565-6577. View Abstract
  38. Measuring Integrin Conformational Change on the Cell Surface with Super-Resolution Microscopy. Cell Rep. 2018 02 13; 22(7):1903-1912. View Abstract
  39. High integrin aVß6 affinity reached by hybrid domain deletion slows ligand-binding on-rate. Proc Natl Acad Sci U S A. 2018 02 13; 115(7):E1429-E1436. View Abstract
  40. Tolloid cleavage activates latent GDF8 by priming the pro-complex for dissociation. EMBO J. 2018 02 01; 37(3):384-397. View Abstract
  41. Direction of actin flow dictates integrin LFA-1 orientation during leukocyte migration. Nat Commun. 2017 12 11; 8(1):2047. View Abstract
  42. Energy landscape differences among integrins establish the framework for understanding activation. J Cell Biol. 2018 01 02; 217(1):397-412. View Abstract
  43. Prodomain-growth factor swapping in the structure of pro-TGF-ß1. J Biol Chem. 2018 02 02; 293(5):1579-1589. View Abstract
  44. Structural basis of regulation of von Willebrand factor binding to glycoprotein Ib. J Biol Chem. 2014 Feb 28; 289(9):5565-79. View Abstract
  45. An internal ligand-bound, metastable state of a leukocyte integrin, aXß2. J Cell Biol. 2013 Nov 25; 203(4):629-42. View Abstract
  46. How natalizumab binds and antagonizes a4 integrins. J Biol Chem. 2013 Nov 08; 288(45):32314-32325. View Abstract
  47. Complete integrin headpiece opening in eight steps. J Cell Biol. 2013 Jun 24; 201(7):1053-68. View Abstract
  48. Release of cellular tension signals self-restorative ventral lamellipodia to heal barrier micro-wounds. J Cell Biol. 2013 Apr 29; 201(3):449-65. View Abstract
  49. Mechanisms by which von Willebrand disease mutations destabilize the A2 domain. J Biol Chem. 2013 Mar 01; 288(9):6317-24. View Abstract
  50. Domain 1 of mucosal addressin cell adhesion molecule has an I1-set fold and a flexible integrin-binding loop. J Biol Chem. 2013 Mar 01; 288(9):6284-94. View Abstract
  51. Shape change in the receptor for gliding motility in Plasmodium sporozoites. Proc Natl Acad Sci U S A. 2012 Dec 26; 109(52):21420-5. View Abstract
  52. a(V)ß(3) integrin crystal structures and their functional implications. Biochemistry. 2012 Nov 06; 51(44):8814-28. View Abstract
  53. Mechanisms for kinase-mediated dimerization of the epidermal growth factor receptor. J Biol Chem. 2012 Nov 02; 287(45):38244-53. View Abstract
  54. Complex structure of engineered modular domains defining molecular interaction between ICAM-1 and integrin LFA-1. PLoS One. 2012; 7(8):e44124. View Abstract
  55. The RGD finger of Del-1 is a unique structural feature critical for integrin binding. FASEB J. 2012 Aug; 26(8):3412-20. View Abstract
  56. Unexpected fold in the circumsporozoite protein target of malaria vaccines. Proc Natl Acad Sci U S A. 2012 May 15; 109(20):7817-22. View Abstract
  57. Sequence and structure relationships within von Willebrand factor. Blood. 2012 Jul 12; 120(2):449-58. View Abstract
  58. Antigen recognition is facilitated by invadosome-like protrusions formed by memory/effector T cells. J Immunol. 2012 Apr 15; 188(8):3686-99. View Abstract
  59. Structure-guided design of a high-affinity platelet integrin aIIbß3 receptor antagonist that disrupts Mg²? binding to the MIDAS. Sci Transl Med. 2012 Mar 14; 4(125):125ra32. View Abstract
  60. Molecular basis for complement recognition by integrin aXß2. Proc Natl Acad Sci U S A. 2012 Mar 20; 109(12):4586-91. View Abstract
  61. Calcium stabilizes the von Willebrand factor A2 domain by promoting refolding. Proc Natl Acad Sci U S A. 2012 Mar 06; 109(10):3742-7. View Abstract
  62. GARP regulates the bioavailability and activation of TGFß. Mol Biol Cell. 2012 Mar; 23(6):1129-39. View Abstract
  63. Structural specializations of a(4)ß(7), an integrin that mediates rolling adhesion. J Cell Biol. 2012 Jan 09; 196(1):131-46. View Abstract
  64. Integrin inside-out signaling and the immunological synapse. Curr Opin Cell Biol. 2012 Feb; 24(1):107-15. View Abstract
  65. The C-terminal aI domain linker as a critical structural element in the conformational activation of aI integrins. J Biol Chem. 2011 Dec 09; 286(49):42115-42122. View Abstract
  66. Regulation of integrin affinity on cell surfaces. EMBO J. 2011 Sep 23; 30(23):4712-27. View Abstract
  67. A pH-regulated dimeric bouquet in the structure of von Willebrand factor. EMBO J. 2011 Aug 19; 30(19):4098-111. View Abstract
  68. Intact alphaIIbbeta3 integrin is extended after activation as measured by solution X-ray scattering and electron microscopy. J Biol Chem. 2011 Oct 07; 286(40):35218-26. View Abstract
  69. Simultaneous visualization of the extracellular and cytoplasmic domains of the epidermal growth factor receptor. Nat Struct Mol Biol. 2011 Aug 07; 18(9):984-9. View Abstract
  70. Biology and physics of von Willebrand factor concatamers. J Thromb Haemost. 2011 Jul; 9 Suppl 1:130-43. View Abstract
  71. Latent TGF-ß structure and activation. Nature. 2011 Jun 15; 474(7351):343-9. View Abstract
  72. Induction by IL 1 and interferon-?: tissue distribution, biochemistry, and function of a natural adherence molecule (ICAM-1). J. Immunol. 1986. 137: 245-254. J Immunol. 2011 May 01; 186(9):5024-33. View Abstract
  73. A human intercellular adhesion molecule (ICAM-1) distinct from LFA-1. J. Immunol. 1986. 137: 1270-1274. J Immunol. 2011 May 01; 186(9):5034-8. View Abstract
  74. A novel calcium-binding site of von Willebrand factor A2 domain regulates its cleavage by ADAMTS13. Blood. 2011 Apr 28; 117(17):4623-31. View Abstract
  75. Cation-pi interaction regulates ligand-binding affinity and signaling of integrin alpha4beta7. Proc Natl Acad Sci U S A. 2010 Dec 14; 107(50):21388-93. View Abstract
  76. Tests of integrin transmembrane domain homo-oligomerization during integrin ligand binding and signaling. J Biol Chem. 2011 Jan 21; 286(3):1860-7. View Abstract
  77. Structural evidence for loose linkage between ligand binding and kinase activation in the epidermal growth factor receptor. Mol Cell Biol. 2010 Nov; 30(22):5432-43. View Abstract
  78. A mechanically stabilized receptor-ligand flex-bond important in the vasculature. Nature. 2010 Aug 19; 466(7309):992-5. View Abstract
  79. Requirement of open headpiece conformation for activation of leukocyte integrin alphaXbeta2. Proc Natl Acad Sci U S A. 2010 Aug 17; 107(33):14727-32. View Abstract
  80. Closed headpiece of integrin aIIbß3 and its complex with an aIIbß3-specific antagonist that does not induce opening. Blood. 2010 Dec 02; 116(23):5050-9. View Abstract
  81. Modulation of integrin activation by an entropic spring in the {beta}-knee. J Biol Chem. 2010 Oct 22; 285(43):32954-32966. View Abstract
  82. Engineering of single Ig superfamily domain of intercellular adhesion molecule 1 (ICAM-1) for native fold and function. J Biol Chem. 2010 May 21; 285(21):15906-15. View Abstract
  83. Structure of an integrin with an alphaI domain, complement receptor type 4. EMBO J. 2010 Feb 03; 29(3):666-79. View Abstract
  84. Structural basis of activation-dependent binding of ligand-mimetic antibody AL-57 to integrin LFA-1. Proc Natl Acad Sci U S A. 2009 Oct 27; 106(43):18345-50. View Abstract
  85. Mechanoenzymatic cleavage of the ultralarge vascular protein von Willebrand factor. Science. 2009 Jun 05; 324(5932):1330-4. View Abstract
  86. Structural specializations of A2, a force-sensing domain in the ultralarge vascular protein von Willebrand factor. Proc Natl Acad Sci U S A. 2009 Jun 09; 106(23):9226-31. View Abstract
  87. The structure of a receptor with two associating transmembrane domains on the cell surface: integrin alphaIIbbeta3. Mol Cell. 2009 Apr 24; 34(2):234-49. View Abstract
  88. The novel S527F mutation in the integrin beta3 chain induces a high affinity alphaIIbbeta3 receptor by hindering adoption of the bent conformation. J Biol Chem. 2009 May 29; 284(22):14914-20. View Abstract
  89. Structural basis for selectin mechanochemistry. Proc Natl Acad Sci U S A. 2009 Jan 06; 106(1):91-6. View Abstract
  90. Transmission of allostery through the lectin domain in selectin-mediated cell adhesion. Proc Natl Acad Sci U S A. 2009 Jan 06; 106(1):85-90. View Abstract
  91. Structure of a complete integrin ectodomain in a physiologic resting state and activation and deactivation by applied forces. Mol Cell. 2008 Dec 26; 32(6):849-61. View Abstract
  92. Rationally designed integrin beta3 mutants stabilized in the high affinity conformation. J Biol Chem. 2009 Feb 06; 284(6):3917-24. View Abstract
  93. Functional and structural stability of the epidermal growth factor receptor in detergent micelles and phospholipid nanodiscs. Biochemistry. 2008 Sep 30; 47(39):10314-23. View Abstract
  94. Structural basis for distinctive recognition of fibrinogen gammaC peptide by the platelet integrin alphaIIbbeta3. J Cell Biol. 2008 Aug 25; 182(4):791-800. View Abstract
  95. An unusual allosteric mobility of the C-terminal helix of a high-affinity alphaL integrin I domain variant bound to ICAM-5. Mol Cell. 2008 Aug 08; 31(3):432-7. View Abstract
  96. Trans-cellular migration: cell-cell contacts get intimate. Curr Opin Cell Biol. 2008 Oct; 20(5):533-40. View Abstract
  97. Nonmuscle myosin heavy chain IIA mediates integrin LFA-1 de-adhesion during T lymphocyte migration. J Exp Med. 2008 Jan 21; 205(1):195-205. View Abstract
  98. Structural plasticity in Ig superfamily domain 4 of ICAM-1 mediates cell surface dimerization. Proc Natl Acad Sci U S A. 2007 Sep 25; 104(39):15358-63. View Abstract
  99. Specific and covalent labeling of a membrane protein with organic fluorochromes and quantum dots. Proc Natl Acad Sci U S A. 2007 Sep 11; 104(37):14753-8. View Abstract
  100. Binding between the integrin alphaXbeta2 (CD11c/CD18) and heparin. J Biol Chem. 2007 Oct 19; 282(42):30869-77. View Abstract
  101. The connection between metal ion affinity and ligand affinity in integrin I domains. Biochim Biophys Acta. 2007 Sep; 1774(9):1148-55. View Abstract
  102. Requirement of alpha and beta subunit transmembrane helix separation for integrin outside-in signaling. Blood. 2007 Oct 01; 110(7):2475-83. View Abstract
  103. Transcellular diapedesis is initiated by invasive podosomes. Immunity. 2007 Jun; 26(6):784-97. View Abstract
  104. Tests of the extension and deadbolt models of integrin activation. J Biol Chem. 2007 Apr 20; 282(16):11914-20. View Abstract
  105. Structural basis of integrin regulation and signaling. Annu Rev Immunol. 2007; 25:619-47. View Abstract
  106. Importance of force linkage in mechanochemistry of adhesion receptors. Biochemistry. 2006 Dec 19; 45(50):15020-8. View Abstract
  107. Structural transitions of complement component C3 and its activation products. Proc Natl Acad Sci U S A. 2006 Dec 26; 103(52):19737-42. View Abstract
  108. Complement and the multifaceted functions of VWA and integrin I domains. Structure. 2006 Nov; 14(11):1611-6. View Abstract
  109. A small molecule agonist of an integrin, alphaLbeta2. J Biol Chem. 2006 Dec 08; 281(49):37904-12. View Abstract
  110. Activation of leukocyte beta2 integrins by conversion from bent to extended conformations. Immunity. 2006 Oct; 25(4):583-94. View Abstract
  111. A high affinity human antibody antagonist of P-selectin mediated rolling. Biochem Biophys Res Commun. 2006 Nov 24; 350(3):508-13. View Abstract
  112. AL-57, a ligand-mimetic antibody to integrin LFA-1, reveals chemokine-induced affinity up-regulation in lymphocytes. Proc Natl Acad Sci U S A. 2006 Sep 19; 103(38):13991-6. View Abstract
  113. Regulation of outside-in signaling and affinity by the beta2 I domain of integrin alphaLbeta2. Proc Natl Acad Sci U S A. 2006 Aug 29; 103(35):13062-7. View Abstract
  114. Integrin structures and conformational signaling. Curr Opin Cell Biol. 2006 Oct; 18(5):579-86. View Abstract
  115. Identification and characterization of a human monoclonal antagonistic antibody AL-57 that preferentially binds the high-affinity form of lymphocyte function-associated antigen-1. J Leukoc Biol. 2006 Oct; 80(4):905-14. View Abstract
  116. Remodeling of the lectin-EGF-like domain interface in P- and L-selectin increases adhesiveness and shear resistance under hydrodynamic force. Nat Immunol. 2006 Aug; 7(8):883-9. View Abstract
  117. Immunoprecipitation. Curr Protoc Neurosci. 2006 May; Chapter 5:Unit 5.24. View Abstract
  118. Directed evolution to probe protein allostery and integrin I domains of 200,000-fold higher affinity. Proc Natl Acad Sci U S A. 2006 Apr 11; 103(15):5758-63. View Abstract
  119. Transition from rolling to firm adhesion can be mimicked by extension of integrin alphaLbeta2 in an intermediate affinity state. J Biol Chem. 2006 Apr 21; 281(16):10876-82. View Abstract
  120. Rational design of intercellular adhesion molecule-1 (ICAM-1) variants for antagonizing integrin lymphocyte function-associated antigen-1-dependent adhesion. J Biol Chem. 2006 Feb 24; 281(8):5042-9. View Abstract
  121. Two-dimensional kinetics regulation of alphaLbeta2-ICAM-1 interaction by conformational changes of the alphaL-inserted domain. J Biol Chem. 2005 Dec 23; 280(51):42207-18. View Abstract
  122. Disrupting integrin transmembrane domain heterodimerization increases ligand binding affinity, not valency or clustering. Proc Natl Acad Sci U S A. 2005 Mar 08; 102(10):3679-84. View Abstract
  123. An atomic resolution view of ICAM recognition in a complex between the binding domains of ICAM-3 and integrin alphaLbeta2. Proc Natl Acad Sci U S A. 2005 Mar 01; 102(9):3366-71. View Abstract
  124. Exposure of acidic residues as a danger signal for recognition of fibrinogen and other macromolecules by integrin alphaXbeta2. Proc Natl Acad Sci U S A. 2005 Feb 01; 102(5):1614-9. View Abstract
  125. The primacy of affinity over clustering in regulation of adhesiveness of the integrin {alpha}L{beta}2. J Cell Biol. 2004 Dec 20; 167(6):1241-53. View Abstract
  126. Conversion between three conformational states of integrin I domains with a C-terminal pull spring studied with molecular dynamics. Structure. 2004 Dec; 12(12):2137-47. View Abstract
  127. Contribution of N-linked glycans to the conformation and function of intercellular adhesion molecules (ICAMs). J Biol Chem. 2005 Feb 18; 280(7):5854-61. View Abstract
  128. A transmigratory cup in leukocyte diapedesis both through individual vascular endothelial cells and between them. J Cell Biol. 2004 Oct 25; 167(2):377-88. View Abstract
  129. The integrin alpha-subunit leg extends at a Ca2+-dependent epitope in the thigh/genu interface upon activation. Proc Natl Acad Sci U S A. 2004 Oct 26; 101(43):15422-7. View Abstract
  130. RIAM, an Ena/VASP and Profilin ligand, interacts with Rap1-GTP and mediates Rap1-induced adhesion. Dev Cell. 2004 Oct; 7(4):585-95. View Abstract
  131. The relative influence of metal ion binding sites in the I-like domain and the interface with the hybrid domain on rolling and firm adhesion by integrin alpha4beta7. J Biol Chem. 2004 Dec 31; 279(53):55556-61. View Abstract
  132. Structural basis for allostery in integrins and binding to fibrinogen-mimetic therapeutics. Nature. 2004 Nov 04; 432(7013):59-67. View Abstract
  133. The binding sites for competitive antagonistic, allosteric antagonistic, and agonistic antibodies to the I domain of integrin LFA-1. J Immunol. 2004 Sep 15; 173(6):3972-8. View Abstract
  134. Integrin beta3 regions controlling binding of murine mAb 7E3: implications for the mechanism of integrin alphaIIbbeta3 activation. Proc Natl Acad Sci U S A. 2004 Sep 07; 101(36):13114-20. View Abstract
  135. A specific interface between integrin transmembrane helices and affinity for ligand. PLoS Biol. 2004 Jun; 2(6):e153. View Abstract
  136. Allosteric beta1 integrin antibodies that stabilize the low affinity state by preventing the swing-out of the hybrid domain. J Biol Chem. 2004 Jun 25; 279(26):27466-71. View Abstract
  137. Structural basis for dimerization of ICAM-1 on the cell surface. Mol Cell. 2004 Apr 23; 14(2):269-76. View Abstract
  138. Rolling adhesion through an extended conformation of integrin alphaLbeta2 and relation to alpha I and beta I-like domain interaction. Immunity. 2004 Apr; 20(4):393-406. View Abstract
  139. Boca-dependent maturation of beta-propeller/EGF modules in low-density lipoprotein receptor proteins. EMBO J. 2004 Mar 24; 23(6):1372-80. View Abstract
  140. Activation of integrin beta-subunit I-like domains by one-turn C-terminal alpha-helix deletions. Proc Natl Acad Sci U S A. 2004 Feb 24; 101(8):2333-8. View Abstract
  141. Intersubunit signal transmission in integrins by a receptor-like interaction with a pull spring. Proc Natl Acad Sci U S A. 2004 Mar 02; 101(9):2906-11. View Abstract
  142. The three-dimensional structure of integrins and their ligands, and conformational regulation of cell adhesion. Adv Protein Chem. 2004; 68:29-63. View Abstract
  143. Therapeutic antagonists and the conformational regulation of the beta2 integrins. Curr Top Med Chem. 2004; 4(14):1485-95. View Abstract
  144. Locking the beta3 integrin I-like domain into high and low affinity conformations with disulfides. J Biol Chem. 2004 Mar 12; 279(11):10215-21. View Abstract
  145. Endothelial cells proactively form microvilli-like membrane projections upon intercellular adhesion molecule 1 engagement of leukocyte LFA-1. J Immunol. 2003 Dec 01; 171(11):6135-44. View Abstract
  146. Bistable regulation of integrin adhesiveness by a bipolar metal ion cluster. Nat Struct Biol. 2003 Dec; 10(12):995-1001. View Abstract
  147. Integrin avidity regulation: are changes in affinity and conformation underemphasized? Curr Opin Cell Biol. 2003 Oct; 15(5):547-56. View Abstract
  148. Bidirectional transmembrane signaling by cytoplasmic domain separation in integrins. Science. 2003 Sep 19; 301(5640):1720-5. View Abstract
  149. Structure of integrin alpha5beta1 in complex with fibronectin. EMBO J. 2003 Sep 15; 22(18):4607-15. View Abstract
  150. Small molecule integrin antagonists that bind to the beta2 subunit I-like domain and activate signals in one direction and block them in the other. Immunity. 2003 Sep; 19(3):391-402. View Abstract
  151. Therapeutic antagonists and conformational regulation of integrin function. Nat Rev Drug Discov. 2003 Sep; 2(9):703-16. View Abstract
  152. Overlapping and selective roles of endothelial intercellular adhesion molecule-1 (ICAM-1) and ICAM-2 in lymphocyte trafficking. J Immunol. 2003 Sep 01; 171(5):2588-93. View Abstract
  153. Complex between nidogen and laminin fragments reveals a paradigmatic beta-propeller interface. Nature. 2003 Aug 21; 424(6951):969-74. View Abstract
  154. The critical cytoplasmic regions of the alphaL/beta2 integrin in Rap1-induced adhesion and migration. Mol Biol Cell. 2003 Jun; 14(6):2570-82. View Abstract
  155. Stabilizing the open conformation of the integrin headpiece with a glycan wedge increases affinity for ligand. Proc Natl Acad Sci U S A. 2003 Mar 04; 100(5):2403-8. View Abstract
  156. High affinity ligand binding by integrins does not involve head separation. J Biol Chem. 2003 May 09; 278(19):17185-9. View Abstract
  157. Structure and allosteric regulation of the alpha X beta 2 integrin I domain. Proc Natl Acad Sci U S A. 2003 Feb 18; 100(4):1873-8. View Abstract
  158. Structures of the alpha L I domain and its complex with ICAM-1 reveal a shape-shifting pathway for integrin regulation. Cell. 2003 Jan 10; 112(1):99-111. View Abstract
  159. Stabilizing the integrin alpha M inserted domain in alternative conformations with a range of engineered disulfide bonds. Proc Natl Acad Sci U S A. 2002 Dec 24; 99(26):16737-41. View Abstract
  160. Predicted and experimental structures of integrins and beta-propellers. Curr Opin Struct Biol. 2002 Dec; 12(6):802-13. View Abstract
  161. Transition from rolling to firm adhesion is regulated by the conformation of the I domain of the integrin lymphocyte function-associated antigen-1. J Biol Chem. 2002 Dec 27; 277(52):50255-62. View Abstract
  162. Measurement of selectin tether bond lifetimes. Biophys J. 2002 Oct; 83(4):2318-20; author reply 2320-3. View Abstract
  163. Archaeal surface layer proteins contain beta propeller, PKD, and beta helix domains and are related to metazoan cell surface proteins. Structure. 2002 Oct; 10(10):1453-64. View Abstract
  164. Global conformational rearrangements in integrin extracellular domains in outside-in and inside-out signaling. Cell. 2002 Sep 06; 110(5):599-11. View Abstract
  165. Integrin activation and structural rearrangement. Immunol Rev. 2002 Aug; 186:141-63. View Abstract
  166. Chondroitin sulfate B exerts its inhibitory effect on secondary lymphoid tissue chemokine (SLC) by binding to the C-terminus of SLC. Biochim Biophys Acta. 2002 Jul 03; 1571(3):219-24. View Abstract
  167. César Milstein, the father of modern immunology. Nat Immunol. 2002 Jun; 3(6):501-3. View Abstract
  168. Immunology. Retrospective: César Milstein (1927-2002). Science. 2002 May 17; 296(5571):1253. View Abstract
  169. The role of the specificity-determining loop of the integrin beta subunit I-like domain in autonomous expression, association with the alpha subunit, and ligand binding. Biochemistry. 2002 Apr 02; 41(13):4339-47. View Abstract
  170. The genome of M. acetivorans reveals extensive metabolic and physiological diversity. Genome Res. 2002 Apr; 12(4):532-42. View Abstract
  171. Cysteine-rich module structure reveals a fulcrum for integrin rearrangement upon activation. Nat Struct Biol. 2002 Apr; 9(4):282-7. View Abstract
  172. Role for CCR7 ligands in the emigration of newly generated T lymphocytes from the neonatal thymus. Immunity. 2002 Feb; 16(2):205-18. View Abstract
  173. Activation-induced conformational changes in the I domain region of lymphocyte function-associated antigen 1. J Biol Chem. 2002 Mar 22; 277(12):10638-41. View Abstract
  174. Molecular basis for interaction between Icap1 alpha PTB domain and beta 1 integrin. J Biol Chem. 2002 Mar 08; 277(10):8140-5. View Abstract
  175. Kinetic and mechanical basis of rolling through an integrin and novel Ca2+-dependent rolling and Mg2+-dependent firm adhesion modalities for the alpha 4 beta 7-MAdCAM-1 interaction. Biochemistry. 2001 Nov 20; 40(46):13972-9. View Abstract
  176. Conformational regulation of integrin structure and function. Annu Rev Biophys Biomol Struct. 2002; 31:485-516. View Abstract
  177. Definition of EGF-like, closely interacting modules that bear activation epitopes in integrin beta subunits. Proc Natl Acad Sci U S A. 2001 Sep 25; 98(20):11175-80. View Abstract
  178. Amino acid residues in the alpha IIb subunit that are critical for ligand binding to integrin alpha IIbbeta 3 are clustered in the beta-propeller model. J Biol Chem. 2001 Nov 23; 276(47):44275-83. View Abstract
  179. Effector differentiation is not prerequisite for generation of memory cytotoxic T lymphocytes. J Clin Invest. 2001 Sep; 108(6):871-8. View Abstract
  180. IL-8 production in human lung fibroblasts and epithelial cells activated by the Pseudomonas autoinducer N-3-oxododecanoyl homoserine lactone is transcriptionally regulated by NF-kappa B and activator protein-2. J Immunol. 2001 Jul 01; 167(1):366-74. View Abstract
  181. Dimerization and the effectiveness of ICAM-1 in mediating LFA-1-dependent adhesion. Proc Natl Acad Sci U S A. 2001 Jun 05; 98(12):6830-5. View Abstract
  182. Ultrastructure and function of dimeric, soluble intercellular adhesion molecule-1 (ICAM-1). J Biol Chem. 2001 Aug 03; 276(31):29019-27. View Abstract
  183. Implications for familial hypercholesterolemia from the structure of the LDL receptor YWTD-EGF domain pair. Nat Struct Biol. 2001 Jun; 8(6):499-504. View Abstract
  184. Reversibly locking a protein fold in an active conformation with a disulfide bond: integrin alphaL I domains with high affinity and antagonist activity in vivo. Proc Natl Acad Sci U S A. 2001 May 22; 98(11):6009-14. View Abstract
  185. Epitope mapping of antibodies to the C-terminal region of the integrin beta 2 subunit reveals regions that become exposed upon receptor activation. J Immunol. 2001 May 01; 166(9):5629-37. View Abstract
  186. Expression of stromal-derived factor-1 is decreased by IL-1 and TNF and in dermal wound healing. J Immunol. 2001 May 01; 166(9):5749-54. View Abstract
  187. C-terminal opening mimics 'inside-out' activation of integrin alpha5beta1. Nat Struct Biol. 2001 May; 8(5):412-6. View Abstract
  188. Immunoaffinity chromatography. Curr Protoc Protein Sci. 2001 May; Chapter 9:Unit 9.5. View Abstract
  189. Immunoprecipitation. Curr Protoc Protein Sci. 2001 May; Chapter 9:Unit 9.8. View Abstract
  190. Immunoaffinity chromatography. Curr Protoc Immunol. 2001 May; Chapter 8:8.2.1-8.2.9. View Abstract
  191. Immunoprecipitation. Curr Protoc Immunol. 2001 May; Chapter 8:Unit 8.3. View Abstract
  192. An isolated, surface-expressed I domain of the integrin alphaLbeta2 is sufficient for strong adhesive function when locked in the open conformation with a disulfide bond. Proc Natl Acad Sci U S A. 2001 Feb 27; 98(5):2387-92. View Abstract
  193. Locking in alternate conformations of the integrin alphaLbeta2 I domain with disulfide bonds reveals functional relationships among integrin domains. Proc Natl Acad Sci U S A. 2001 Feb 27; 98(5):2393-8. View Abstract
  194. Association of the membrane proximal regions of the alpha and beta subunit cytoplasmic domains constrains an integrin in the inactive state. J Biol Chem. 2001 May 04; 276(18):14642-8. View Abstract
  195. Selectin receptor-ligand bonds: Formation limited by shear rate and dissociation governed by the Bell model. Proc Natl Acad Sci U S A. 2001 Jan 30; 98(3):950-5. View Abstract
  196. LFA-1 expression on target cells promotes human immunodeficiency virus type 1 infection and transmission. J Virol. 2001 Jan; 75(2):1077-82. View Abstract
  197. Amino acid residues in the PSI domain and cysteine-rich repeats of the integrin beta2 subunit that restrain activation of the integrin alpha(X)beta(2). J Biol Chem. 2001 Mar 09; 276(10):6922-9. View Abstract
  198. A novel Ca2+ binding beta hairpin loop better resembles integrin sequence motifs than the EF hand. Cell. 2000 Aug 04; 102(3):275-7. View Abstract
  199. Computational design of an integrin I domain stabilized in the open high affinity conformation. Nat Struct Biol. 2000 Aug; 7(8):674-8. View Abstract
  200. The top of the inserted-like domain of the integrin lymphocyte function-associated antigen-1 beta subunit contacts the alpha subunit beta -propeller domain near beta-sheet 3. J Biol Chem. 2000 Jul 21; 275(29):22202-12. View Abstract
  201. Folding and function of I domain-deleted Mac-1 and lymphocyte function-associated antigen-1. J Biol Chem. 2000 Jul 21; 275(29):21877-82. View Abstract
  202. Structural and functional studies with antibodies to the integrin beta 2 subunit. A model for the I-like domain. J Biol Chem. 2000 Jul 14; 275(28):21514-24. View Abstract
  203. Maturation decreases responsiveness of human bone marrow B lineage cells to stromal-derived factor 1 (SDF-1). J Leukoc Biol. 1999 Oct; 66(4):667-73. View Abstract
  204. Domains in plexins: links to integrins and transcription factors. Trends Biochem Sci. 1999 Jul; 24(7):261-3. View Abstract
  205. The chemokine receptor CXCR4 is required for the retention of B lineage and granulocytic precursors within the bone marrow microenvironment. Immunity. 1999 Apr; 10(4):463-71. View Abstract
  206. Lymphocyte function-associated antigen-1 binding residues in intercellular adhesion molecule-2 (ICAM-2) and the integrin binding surface in the ICAM subfamily. Proc Natl Acad Sci U S A. 1999 Mar 16; 96(6):3017-22. View Abstract
  207. Conformational changes in tertiary structure near the ligand binding site of an integrin I domain. Proc Natl Acad Sci U S A. 1999 Mar 02; 96(5):2215-20. View Abstract
  208. An automatic braking system that stabilizes leukocyte rolling by an increase in selectin bond number with shear. J Cell Biol. 1999 Jan 11; 144(1):185-200. View Abstract
  209. Role of ICAM-1 and ICAM-2 and alternate CD11/CD18 ligands in neutrophil transendothelial migration. J Leukoc Biol. 1999 Jan; 65(1):117-26. View Abstract
  210. Prolonged eosinophil accumulation in allergic lung interstitium of ICAM-2 deficient mice results in extended hyperresponsiveness. Immunity. 1999 Jan; 10(1):9-19. View Abstract
  211. Mutational analysis of MAdCAM-1/alpha4beta7 interactions reveals significant binding determinants in both the first and second immunuglobulin domains. Cell Adhes Commun. 1999; 7(3):167-81. View Abstract
  212. Interaction of very late antigen-4 with VCAM-1 supports transendothelial chemotaxis of monocytes by facilitating lateral migration. J Immunol. 1998 Dec 15; 161(12):6825-34. View Abstract
  213. Effects of a monoclonal antibody to P-selectin on recovery of neonatal lamb hearts after cold cardioplegic ischemia. Circulation. 1998 Nov 10; 98(19 Suppl):II391-7; discussion II397-8. View Abstract
  214. An extracellular beta-propeller module predicted in lipoprotein and scavenger receptors, tyrosine kinases, epidermal growth factor precursor, and extracellular matrix components. J Mol Biol. 1998 Nov 06; 283(4):837-62. View Abstract
  215. The kinetics and shear threshold of transient and rolling interactions of L-selectin with its ligand on leukocytes. Proc Natl Acad Sci U S A. 1998 Sep 29; 95(20):11631-6. View Abstract
  216. Protection from lymphoma cell metastasis in ICAM-1 mutant mice: a posthoming event. J Immunol. 1998 Sep 01; 161(5):2333-8. View Abstract
  217. Impaired B-lymphopoiesis, myelopoiesis, and derailed cerebellar neuron migration in CXCR4- and SDF-1-deficient mice. Proc Natl Acad Sci U S A. 1998 Aug 04; 95(16):9448-53. View Abstract
  218. The domain structure of ICAM-1 and the kinetics of binding to rhinovirus. J Virol. 1998 Jul; 72(7):6244-6. View Abstract
  219. The structure of immunoglobulin superfamily domains 1 and 2 of MAdCAM-1 reveals novel features important for integrin recognition. Structure. 1998 Jun 15; 6(6):793-801. View Abstract
  220. The structure of the beta-propeller domain and C-terminal region of the integrin alphaM subunit. Dependence on beta subunit association and prediction of domains. J Biol Chem. 1998 Jun 12; 273(24):15138-47. View Abstract
  221. Structural specializations of immunoglobulin superfamily members for adhesion to integrins and viruses. Immunol Rev. 1998 Jun; 163:197-215. View Abstract
  222. Differential requirements for LFA-1 binding to ICAM-1 and LFA-1-mediated cell aggregation. J Immunol. 1998 May 01; 160(9):4208-16. View Abstract
  223. The C-C chemokine receptor CCR3 participates in stimulation of eosinophil arrest on inflammatory endothelium in shear flow. J Clin Invest. 1998 May 01; 101(9):2017-24. View Abstract
  224. Modifying the mechanical property and shear threshold of L-selectin adhesion independently of equilibrium properties. Nature. 1998 Apr 30; 392(6679):930-3. View Abstract
  225. Experimental support for a beta-propeller domain in integrin alpha-subunits and a calcium binding site on its lower surface. Proc Natl Acad Sci U S A. 1998 Apr 28; 95(9):4870-5. View Abstract
  226. Cardiac graft intercellular adhesion molecule-1 (ICAM-1) and interleukin-1 expression mediate primary isograft failure and induction of ICAM-1 in organs remote from the site of transplantation. Circ Res. 1998 Apr 20; 82(7):762-72. View Abstract
  227. A dimeric crystal structure for the N-terminal two domains of intercellular adhesion molecule-1. Proc Natl Acad Sci U S A. 1998 Apr 14; 95(8):4134-9. View Abstract
  228. B lymphocyte chemotaxis regulated in association with microanatomic localization, differentiation state, and B cell receptor engagement. J Exp Med. 1998 Mar 02; 187(5):753-62. View Abstract
  229. The chemokine receptor CXCR3 mediates rapid and shear-resistant adhesion-induction of effector T lymphocytes by the chemokines IP10 and Mig. Eur J Immunol. 1998 Mar; 28(3):961-72. View Abstract
  230. L-Selectin ligands that are O-glycoprotease resistant and distinct from MECA-79 antigen are sufficient for tethering and rolling of lymphocytes on human high endothelial venules. J Cell Biol. 1998 Feb 09; 140(3):721-31. View Abstract
  231. Use of murine CXCR-4 as a second receptor by some T-cell-tropic human immunodeficiency viruses. J Virol. 1998 Feb; 72(2):1652-6. View Abstract
  232. Transendothelial chemotaxis of human alpha/beta and gamma/delta T lymphocytes to chemokines. Eur J Immunol. 1998 Jan; 28(1):104-13. View Abstract
  233. Defining extracellular integrin alpha-chain sites that affect cell adhesion and adhesion strengthening without altering soluble ligand binding. Mol Biol Cell. 1997 Dec; 8(12):2647-57. View Abstract
  234. Neutrophil accumulation on activated, surface-adherent platelets in flow is mediated by interaction of Mac-1 with fibrinogen bound to alphaIIbbeta3 and stimulated by platelet-activating factor. J Clin Invest. 1997 Oct 15; 100(8):2085-93. View Abstract
  235. P-selectin, L-selectin, and alpha 4 integrin have distinct roles in eosinophil tethering and arrest on vascular endothelial cells under physiological flow conditions. J Immunol. 1997 Oct 15; 159(8):3929-39. View Abstract
  236. Role of alpha L beta 2 integrin avidity in transendothelial chemotaxis of mononuclear cells. J Immunol. 1997 Oct 15; 159(8):3968-75. View Abstract
  237. The kinetics of L-selectin tethers and the mechanics of selectin-mediated rolling. J Cell Biol. 1997 Sep 08; 138(5):1169-80. View Abstract
  238. Functional expression of the CXC-chemokine receptor-4/fusin on mouse microglial cells and astrocytes. J Immunol. 1997 Jul 15; 159(2):905-11. View Abstract
  239. The alpha subunit cytoplasmic domain regulates the assembly and adhesiveness of integrin lymphocyte function-associated antigen-1. J Immunol. 1997 Jul 01; 159(1):268-78. View Abstract
  240. Crystal structure of ICAM-2 reveals a distinctive integrin recognition surface. Nature. 1997 May 15; 387(6630):312-5. View Abstract
  241. Tenascin supports lymphocyte rolling. J Cell Biol. 1997 May 05; 137(3):755-65. View Abstract
  242. Folding of the conserved domain but not of flanking regions in the integrin beta2 subunit requires association with the alpha subunit. Proc Natl Acad Sci U S A. 1997 Apr 01; 94(7):3156-61. View Abstract
  243. Folding of the beta-propeller domain of the integrin alphaL subunit is independent of the I domain and dependent on the beta2 subunit. Proc Natl Acad Sci U S A. 1997 Apr 01; 94(7):3162-7. View Abstract
  244. Rolling and transient tethering of leukocytes on antibodies reveal specializations of selectins. Proc Natl Acad Sci U S A. 1997 Apr 01; 94(7):3172-7. View Abstract
  245. The HIV coreceptors CXCR4 and CCR5 are differentially expressed and regulated on human T lymphocytes. Proc Natl Acad Sci U S A. 1997 Mar 04; 94(5):1925-30. View Abstract
  246. Contrasting responses to multiple chemotactic stimuli in transendothelial migration: heterologous desensitization in neutrophils and augmentation of migration in eosinophils. J Immunol. 1997 Mar 01; 158(5):2340-9. View Abstract
  247. Folding of the N-terminal, ligand-binding region of integrin alpha-subunits into a beta-propeller domain. Proc Natl Acad Sci U S A. 1997 Jan 07; 94(1):65-72. View Abstract
  248. The chemokine SDF-1 is a chemoattractant for human CD34+ hematopoietic progenitor cells and provides a new mechanism to explain the mobilization of CD34+ progenitors to peripheral blood. J Exp Med. 1997 Jan 06; 185(1):111-20. View Abstract
  249. Characterization of lymphocyte function-associated antigen 1 (LFA-1)-deficient T cell lines: the alphaL and beta2 subunits are interdependent for cell surface expression. J Immunol. 1997 Jan 01; 158(1):273-9. View Abstract
  250. The faster kinetics of L-selectin than of E-selectin and P-selectin rolling at comparable binding strength. J Immunol. 1997 Jan 01; 158(1):405-13. View Abstract
  251. Molecular cloning and characterization of a murine pre-B-cell growth-stimulating factor/stromal cell-derived factor 1 receptor, a murine homolog of the human immunodeficiency virus 1 entry coreceptor fusin. Proc Natl Acad Sci U S A. 1996 Dec 10; 93(25):14726-9. View Abstract
  252. A differential role for cell shape in neutrophil tethering and rolling on endothelial selectins under flow. J Immunol. 1996 Dec 01; 157(11):5085-96. View Abstract
  253. Sialylated, fucosylated ligands for L-selectin expressed on leukocytes mediate tethering and rolling adhesions in physiologic flow conditions. J Cell Biol. 1996 Nov; 135(3):837-48. View Abstract
  254. Interactions through L-selectin between leukocytes and adherent leukocytes nucleate rolling adhesions on selectins and VCAM-1 in shear flow. J Cell Biol. 1996 Nov; 135(3):849-65. View Abstract
  255. Differential regulation of beta 1 and beta 2 integrin avidity by chemoattractants in eosinophils. Proc Natl Acad Sci U S A. 1996 Oct 01; 93(20):10939-44. View Abstract
  256. Localization of the binding site on intercellular adhesion molecule-3 (ICAM-3) for lymphocyte function-associated antigen 1 (LFA-1). J Biol Chem. 1996 Sep 27; 271(39):23920-7. View Abstract
  257. A highly efficacious lymphocyte chemoattractant, stromal cell-derived factor 1 (SDF-1) J Exp Med. 1996 Sep 01; 184(3):1101-9. View Abstract
  258. The lymphocyte chemoattractant SDF-1 is a ligand for LESTR/fusin and blocks HIV-1 entry. Nature. 1996 Aug 29; 382(6594):829-33. View Abstract
  259. Quantitation of L-selectin distribution on human leukocyte microvilli by immunogold labeling and electron microscopy. J Histochem Cytochem. 1996 Aug; 44(8):835-44. View Abstract
  260. Sequential regulation of alpha 4 beta 1 and alpha 5 beta 1 integrin avidity by CC chemokines in monocytes: implications for transendothelial chemotaxis. J Cell Biol. 1996 Aug; 134(4):1063-73. View Abstract
  261. CD44 and hyaluronan-dependent rolling interactions of lymphocytes on tonsillar stroma. J Cell Biol. 1996 Aug; 134(4):1075-87. View Abstract
  262. Platelet-mediated lymphocyte delivery to high endothelial venules. Science. 1996 Jul 12; 273(5272):252-5. View Abstract
  263. Role of intercellular adhesion molecule 1 in pathogenesis of staphylococcal arthritis and in host defense against staphylococcal bacteremia. Infect Immun. 1996 Jul; 64(7):2804-7. View Abstract
  264. Neutrophil rolling, arrest, and transmigration across activated, surface-adherent platelets via sequential action of P-selectin and the beta 2-integrin CD11b/CD18. Blood. 1996 Jul 01; 88(1):146-57. View Abstract
  265. Expression and polarization of intercellular adhesion molecule-1 on human intestinal epithelia: consequences for CD11b/CD18-mediated interactions with neutrophils. Mol Med. 1996 Jul; 2(4):489-505. View Abstract
  266. Characterization of murine intercellular adhesion molecule-2. J Immunol. 1996 Jun 15; 156(12):4909-14. View Abstract
  267. Cloning and chromosomal localization of a novel gene-encoding a human beta 2-integrin alpha subunit. Gene. 1996 Jun 01; 171(2):291-4. View Abstract
  268. A schiff base with mildly oxidized carbohydrate ligands stabilizes L-selectin and not P-selectin or E-selectin rolling adhesions in shear flow. J Biol Chem. 1996 Mar 08; 271(10):5404-13. View Abstract
  269. Interactions of human alpha/beta and gamma/delta T lymphocyte subsets in shear flow with E-selectin and P-selectin. J Exp Med. 1996 Mar 01; 183(3):1193-203. View Abstract
  270. Modulation of endothelial cell adhesion by hevin, an acidic protein associated with high endothelial venules. J Biol Chem. 1996 Feb 23; 271(8):4511-7. View Abstract
  271. Intercellular adhesion molecule-1-deficient mice are protected against ischemic renal injury. J Clin Invest. 1996 Feb 15; 97(4):1056-63. View Abstract
  272. The C-C chemokine MCP-1 differentially modulates the avidity of beta 1 and beta 2 integrins on T lymphocytes. Immunity. 1996 Feb; 4(2):179-87. View Abstract
  273. Visualization of CD2 interaction with LFA-3 and determination of the two-dimensional dissociation constant for adhesion receptors in a contact area. J Cell Biol. 1996 Feb; 132(3):465-74. View Abstract
  274. Adhesion through L-selectin requires a threshold hydrodynamic shear. Nature. 1996 Jan 18; 379(6562):266-9. View Abstract
  275. Cerebral protection in homozygous null ICAM-1 mice after middle cerebral artery occlusion. Role of neutrophil adhesion in the pathogenesis of stroke. J Clin Invest. 1996 Jan 01; 97(1):209-16. View Abstract
  276. Characterization of transendothelial chemotaxis of T lymphocytes. J Immunol Methods. 1995 Dec 15; 188(1):97-116. View Abstract
  277. C-C chemokines, but not the C-X-C chemokines interleukin-8 and interferon-gamma inducible protein-10, stimulate transendothelial chemotaxis of T lymphocytes. Eur J Immunol. 1995 Dec; 25(12):3482-8. View Abstract
  278. High avidity state of leukocyte function-associated antigen-1 on rheumatoid synovial fluid T lymphocytes. J Immunol. 1995 Oct 15; 155(8):4118-24. View Abstract
  279. Sialomucin CD34 is the major L-selectin ligand in human tonsil high endothelial venules. J Cell Biol. 1995 Oct; 131(1):261-70. View Abstract
  280. ICAM-1 is required for T cell proliferation but not for anergy or apoptosis induced by Staphylococcus aureus enterotoxin B in vivo. Int Immunol. 1995 Oct; 7(10):1691-8. View Abstract
  281. Ideas crystallized on immunoglobulin superfamily-integrin interactions. Chem Biol. 1995 Oct; 2(10):639-43. View Abstract
  282. Receptor tyrosine kinase stimulates cell-matrix adhesion by phosphatidylinositol 3 kinase and phospholipase C-gamma 1 pathways. Blood. 1995 Sep 15; 86(6):2086-90. View Abstract
  283. High endothelial venules (HEVs): specialized endothelium for lymphocyte migration. Immunol Today. 1995 Sep; 16(9):449-57. View Abstract
  284. Heparin is an adhesive ligand for the leukocyte integrin Mac-1 (CD11b/CD1). J Cell Biol. 1995 Sep; 130(6):1473-82. View Abstract
  285. A binding interface on the I domain of lymphocyte function-associated antigen-1 (LFA-1) required for specific interaction with intercellular adhesion molecule 1 (ICAM-1). J Biol Chem. 1995 Aug 11; 270(32):19008-16. View Abstract
  286. Activation of lymphocyte function-associated molecule-1 (CD11a/CD18) and Mac-1 (CD11b/CD18) mimicked by an antibody directed against CD18. J Immunol. 1995 Jul 15; 155(2):854-66. View Abstract
  287. Regulation of cell-matrix adhesion by receptor tyrosine kinases. Leuk Lymphoma. 1995 Jul; 18(3-4):203-8. View Abstract
  288. Kinetics and thermodynamics of virus binding to receptor. Studies with rhinovirus, intercellular adhesion molecule-1 (ICAM-1), and surface plasmon resonance. J Biol Chem. 1995 Jun 02; 270(22):13216-24. View Abstract
  289. Specialized functional properties of the integrin alpha 4 cytoplasmic domain. Mol Biol Cell. 1995 Jun; 6(6):661-74. View Abstract
  290. Glycolipid ligands for selectins support leukocyte tethering and rolling under physiologic flow conditions. J Immunol. 1995 May 15; 154(10):5356-66. View Abstract
  291. Activation of natural killer cells by the mAb YTA-1 that recognizes leukocyte function-associated antigen-1. Int Immunol. 1995 May; 7(5):763-9. View Abstract
  292. Lifetime of the P-selectin-carbohydrate bond and its response to tensile force in hydrodynamic flow. Nature. 1995 Apr 06; 374(6522):539-42. View Abstract
  293. Rolling of lymphocytes and neutrophils on peripheral node addressin and subsequent arrest on ICAM-1 in shear flow. Eur J Immunol. 1995 Apr; 25(4):1025-31. View Abstract
  294. Heterogenous glycosylation of ICAM-3 and lack of interaction with Mac-1 and p150,95. Eur J Immunol. 1995 Apr; 25(4):1008-12. View Abstract
  295. The integrin VLA-4 supports tethering and rolling in flow on VCAM-1. J Cell Biol. 1995 Mar; 128(6):1243-53. View Abstract
  296. Expression of glycophosphatidylinositol-anchored and -non-anchored isoforms of vascular cell adhesion molecule 1 in murine stromal and endothelial cells. J Leukoc Biol. 1995 Jan; 57(1):168-73. View Abstract
  297. Cloning from purified high endothelial venule cells of hevin, a close relative of the antiadhesive extracellular matrix protein SPARC. Immunity. 1995 Jan; 2(1):113-23. View Abstract
  298. Traffic signals on endothelium for lymphocyte recirculation and leukocyte emigration. Annu Rev Physiol. 1995; 57:827-72. View Abstract
  299. Distinct cell surface ligands mediate T lymphocyte attachment and rolling on P and E selectin under physiological flow. J Cell Biol. 1994 Dec; 127(5):1485-95. View Abstract
  300. Pathway of rhinovirus disruption by soluble intercellular adhesion molecule 1 (ICAM-1): an intermediate in which ICAM-1 is bound and RNA is released. J Virol. 1994 Sep; 68(9):5882-9. View Abstract
  301. Intercellular adhesion molecules (ICAM)-1 ICAM-2 and ICAM-3 function as counter-receptors for lymphocyte function-associated molecule 1 in human immunodeficiency virus-mediated syncytia formation. Eur J Immunol. 1994 Sep; 24(9):2191-5. View Abstract
  302. A functional integrin ligand on the surface of platelets: intercellular adhesion molecule-2. J Clin Invest. 1994 Sep; 94(3):1243-51. View Abstract
  303. Leukocytosis and resistance to septic shock in intercellular adhesion molecule 1-deficient mice. J Exp Med. 1994 Jul 01; 180(1):95-109. View Abstract
  304. Changes in subcellular localization and surface expression of L-selectin, alkaline phosphatase, and Mac-1 in human neutrophils during stimulation with inflammatory mediators. J Leukoc Biol. 1994 Jul; 56(1):80-7. View Abstract
  305. The dynamic regulation of integrin adhesiveness. Curr Biol. 1994 Jun 01; 4(6):506-17. View Abstract
  306. Neutrophil tethering to and rolling on E-selectin are separable by requirement for L-selectin. Immunity. 1994 May; 1(2):137-45. View Abstract
  307. The leukocyte integrin p150,95 (CD11c/CD18) as a receptor for iC3b. Activation by a heterologous beta subunit and localization of a ligand recognition site to the I domain. J Immunol. 1994 May 01; 152(9):4582-9. View Abstract
  308. Monocyte chemoattractant protein 1 acts as a T-lymphocyte chemoattractant. Proc Natl Acad Sci U S A. 1994 Apr 26; 91(9):3652-6. View Abstract
  309. Residues within a conserved amino acid motif of domains 1 and 4 of VCAM-1 are required for binding to VLA-4. J Cell Biol. 1994 Apr; 125(1):215-22. View Abstract
  310. Cloning and expression of the chicken CD18 cDNA. J Leukoc Biol. 1994 Apr; 55(4):501-6. View Abstract
  311. Steel factor and c-kit regulate cell-matrix adhesion. Blood. 1994 Feb 15; 83(4):1033-8. View Abstract
  312. Characterization of the function of intercellular adhesion molecule (ICAM)-3 and comparison with ICAM-1 and ICAM-2 in immune responses. J Exp Med. 1994 Feb 01; 179(2):619-29. View Abstract
  313. Traffic signals for lymphocyte recirculation and leukocyte emigration: the multistep paradigm. Cell. 1994 Jan 28; 76(2):301-14. View Abstract
  314. CD antigens 1993. J Immunol. 1994 Jan 01; 152(1):1-2. View Abstract
  315. Adhesion molecules in hematopoietic cells. Blood Cells. 1994; 20(1):25-44. View Abstract
  316. Neutrophils roll on E-selectin. J Immunol. 1993 Dec 01; 151(11):6338-46. View Abstract
  317. Characterization of two new CD18 alleles causing severe leukocyte adhesion deficiency. Eur J Immunol. 1993 Nov; 23(11):2792-8. View Abstract
  318. Subcellular localization and dynamics of Mac-1 (alpha m beta 2) in human neutrophils. J Clin Invest. 1993 Sep; 92(3):1467-76. View Abstract
  319. The intracellular bacterium Rhodococcus equi requires Mac-1 to bind to mammalian cells. Infect Immun. 1993 Jul; 61(7):2919-29. View Abstract
  320. CDw50 and ICAM-3: two names for the same molecule. Eur J Immunol. 1993 Jul; 23(7):1508-12. View Abstract
  321. Efficient neutralization and disruption of rhinovirus by chimeric ICAM-1/immunoglobulin molecules. J Virol. 1993 Jun; 67(6):3561-8. View Abstract
  322. Functional studies of truncated soluble intercellular adhesion molecule 1 expressed in Escherichia coli. Antimicrob Agents Chemother. 1993 Jun; 37(6):1278-84. View Abstract
  323. Cloning and expression of intercellular adhesion molecule 3 reveals strong homology to other immunoglobulin family counter-receptors for lymphocyte function-associated antigen 1. J Exp Med. 1993 Apr 01; 177(4):1187-92. View Abstract
  324. Location of the domains of ICAM-1 by immunolabeling and single-molecule electron microscopy. J Leukoc Biol. 1993 Mar; 53(3):342-6. View Abstract
  325. The I domain is a major recognition site on the leukocyte integrin Mac-1 (CD11b/CD18) for four distinct adhesion ligands. J Cell Biol. 1993 Feb; 120(4):1031-43. View Abstract
  326. A subpopulation of Mac-1 (CD11b/CD18) molecules mediates neutrophil adhesion to ICAM-1 and fibrinogen. J Cell Biol. 1993 Jan; 120(2):545-56. View Abstract
  327. Signals on endothelium for lymphocyte recirculation and leukocyte emigration: the area code paradigm. Harvey Lect. 1993-1994; 89:53-103. View Abstract
  328. Soluble intercellular adhesion molecule 1-immunoglobulin G1 immunoadhesin mediates phagocytosis of malaria-infected erythrocytes. J Exp Med. 1992 Nov 01; 176(5):1471-6. View Abstract
  329. Isolation, characterization, and expression of mouse ICAM-2 complementary and genomic DNA. J Immunol. 1992 Oct 15; 149(8):2650-5. View Abstract
  330. Association of intercellular adhesion molecule-1 (ICAM-1) with actin-containing cytoskeleton and alpha-actinin. J Cell Biol. 1992 Sep; 118(5):1223-34. View Abstract
  331. Micromanipulation of adhesion of phorbol 12-myristate-13-acetate-stimulated T lymphocytes to planar membranes containing intercellular adhesion molecule-1. Biophys J. 1992 Jul; 63(1):247-58. View Abstract
  332. Lymphocyte adhesion through very late antigen 4: evidence for a novel binding site in the alternatively spliced domain of vascular cell adhesion molecule 1 and an additional alpha 4 integrin counter-receptor on stimulated endothelium. J Exp Med. 1992 Jun 01; 175(6):1433-42. View Abstract
  333. Internalization of a major group human rhinovirus does not require cytoplasmic or transmembrane domains of ICAM-1. J Immunol. 1992 May 15; 148(10):3271-4. View Abstract
  334. Regulation of locomotion and cell-cell contact area by the LFA-1 and ICAM-1 adhesion receptors. J Immunol. 1992 May 01; 148(9):2654-63. View Abstract
  335. Effect of lengthening lymphocyte function-associated antigen 3 on adhesion to CD2. Mol Biol Cell. 1992 Feb; 3(2):157-66. View Abstract
  336. Micromanipulation of adhesion of a Jurkat cell to a planar bilayer membrane containing lymphocyte function-associated antigen 3 molecules. J Cell Biol. 1992 Feb; 116(4):997-1006. View Abstract
  337. Plasmodium falciparum-infected erythrocytes bind ICAM-1 at a site distinct from LFA-1, Mac-1, and human rhinovirus. Cell. 1992 Jan 10; 68(1):63-9. View Abstract
  338. Leishmania promastigotes require opsonic complement to bind to the human leukocyte integrin Mac-1 (CD11b/CD18). J Cell Biol. 1992 Jan; 116(2):511-20. View Abstract
  339. Intercellular adhesion molecule 3, a third adhesion counter-receptor for lymphocyte function-associated molecule 1 on resting lymphocytes. J Exp Med. 1992 Jan 01; 175(1):185-90. View Abstract
  340. The next cluster of differentiation (CD) workshop. Nature. 1991 Dec 05; 354(6352):415-6. View Abstract
  341. The cytoplasmic domain of the integrin lymphocyte function-associated antigen 1 beta subunit: sites required for binding to intercellular adhesion molecule 1 and the phorbol ester-stimulated phosphorylation site. J Exp Med. 1991 Nov 01; 174(5):1227-38. View Abstract
  342. Motility and ultrastructure of large granular lymphocytes on lipid bilayers reconstituted with adhesion receptors LFA-1, ICAM-1, and two isoforms of LFA-3. J Cell Biol. 1991 Nov; 115(3):861-71. View Abstract
  343. Cell adhesion. A birth certificate for CD2. Nature. 1991 Oct 24; 353(6346):704-5. View Abstract
  344. The sensation and regulation of interactions with the extracellular environment: the cell biology of lymphocyte adhesion receptors. Annu Rev Cell Biol. 1990; 6:359-402. View Abstract
  345. Mechanisms for regulating expression of membrane isoforms of Fc gamma RIII (CD16). Science. 1989 Dec 22; 246(4937):1608-11. View Abstract
  346. Natural killer cell and granulocyte Fc gamma receptor III (CD16) differ in membrane anchor and signal transduction. J Immunol. 1989 Nov 15; 143(10):3283-8. View Abstract
  347. T-cell receptor cross-linking transiently stimulates adhesiveness through LFA-1. Nature. 1989 Oct 19; 341(6243):619-24. View Abstract
  348. Distinct restriction of complement- and cell-mediated lysis. J Immunol. 1989 Jun 01; 142(11):3913-6. View Abstract
  349. Functional cloning of ICAM-2, a cell adhesion ligand for LFA-1 homologous to ICAM-1. Nature. 1989 May 04; 339(6219):61-4. View Abstract
  350. A cell adhesion molecule, ICAM-1, is the major surface receptor for rhinoviruses. Cell. 1989 Mar 10; 56(5):849-53. View Abstract
  351. Leukocyte adhesion deficiency. Aberrant splicing of a conserved integrin sequence causes a moderate deficiency phenotype. J Biol Chem. 1989 Feb 25; 264(6):3588-95. View Abstract
  352. Correlation of CD2 binding and functional properties of multimeric and monomeric lymphocyte function-associated antigen 3. J Exp Med. 1989 Feb 01; 169(2):503-17. View Abstract
  353. Adherence of neutrophils to cultured human microvascular endothelial cells. Stimulation by chemotactic peptides and lipid mediators and dependence upon the Mac-1, LFA-1, p150,95 glycoprotein family. J Clin Invest. 1989 Feb; 83(2):637-46. View Abstract
  354. Primary structure of the leukocyte function-associated molecule-1 alpha subunit: an integrin with an embedded domain defining a protein superfamily. J Cell Biol. 1989 Feb; 108(2):703-12. View Abstract
  355. Human leukocyte adhesion deficiency: molecular basis for a defective immune response to infections of the skin. Curr Probl Dermatol. 1989; 18:106-15. View Abstract
  356. Immunohistologic analysis of the distribution of cell adhesion molecules within the inflammatory synovial microenvironment. Arthritis Rheum. 1989 Jan; 32(1):22-30. View Abstract
  357. Biosynthesis and function of LFA-3 in human mutant cells deficient in phosphatidylinositol-anchored proteins. J Immunol. 1988 Dec 15; 141(12):4283-90. View Abstract
  358. Purified lymphocyte function-associated antigen-3 (LFA-3) activates human thymocytes via the CD2 pathway. J Immunol. 1988 Nov 01; 141(9):2980-5. View Abstract
  359. Epstein-Barr virus latent infection membrane protein alters the human B-lymphocyte phenotype: deletion of the amino terminus abolishes activity. J Virol. 1988 Nov; 62(11):4173-84. View Abstract
  360. Intercellular adhesion molecule-1 (ICAM-1) is involved in the cytolytic T lymphocyte interaction with a human synovial cell line. J Cell Physiol. 1988 Oct; 137(1):173-8. View Abstract
  361. The CD2 ligand LFA-3 activates T cells but depends on the expression and function of the antigen receptor. J Immunol. 1988 Sep 15; 141(6):1904-11. View Abstract
  362. The human leukocyte adhesion glycoprotein Mac-1 (complement receptor type 3, CD11b) alpha subunit. Cloning, primary structure, and relation to the integrins, von Willebrand factor and factor B. J Biol Chem. 1988 Sep 05; 263(25):12403-11. View Abstract
  363. Supergene families meet in the immune system. Immunol Today. 1988 Jul-Aug; 9(7-8):213-5. View Abstract
  364. Lymphocyte function-associated antigen-1 (LFA-1) interaction with intercellular adhesion molecule-1 (ICAM-1) is one of at least three mechanisms for lymphocyte adhesion to cultured endothelial cells. J Cell Biol. 1988 Jul; 107(1):321-31. View Abstract
  365. The major Fc receptor in blood has a phosphatidylinositol anchor and is deficient in paroxysmal nocturnal haemoglobinuria. Nature. 1988 Jun 09; 333(6173):565-7. View Abstract
  366. Chromosomal location of the genes encoding the leukocyte adhesion receptors LFA-1, Mac-1 and p150,95. Identification of a gene cluster involved in cell adhesion. J Exp Med. 1988 May 01; 167(5):1597-607. View Abstract
  367. Adhesion of T lymphoblasts to epidermal keratinocytes is regulated by interferon gamma and is mediated by intercellular adhesion molecule 1 (ICAM-1). J Exp Med. 1988 Apr 01; 167(4):1323-40. View Abstract
  368. Functional evidence that intercellular adhesion molecule-1 (ICAM-1) is a ligand for LFA-1-dependent adhesion in T cell-mediated cytotoxicity. Eur J Immunol. 1988 Apr; 18(4):637-40. View Abstract
  369. Primary structure of ICAM-1 demonstrates interaction between members of the immunoglobulin and integrin supergene families. Cell. 1988 Mar 25; 52(6):925-33. View Abstract
  370. Endothelial activation during interleukin 2 immunotherapy. A possible mechanism for the vascular leak syndrome. J Immunol. 1988 Mar 15; 140(6):1883-8. View Abstract
  371. Human memory T lymphocytes express increased levels of three cell adhesion molecules (LFA-3, CD2, and LFA-1) and three other molecules (UCHL1, CDw29, and Pgp-1) and have enhanced IFN-gamma production. J Immunol. 1988 Mar 01; 140(5):1401-7. View Abstract
  372. ICAM-1 a ligand for LFA-1-dependent adhesion of B, T and myeloid cells. Nature. 1988 Jan 07; 331(6151):86-8. View Abstract
  373. Leukocyte adhesion deficiency: molecular basis and functional consequences. Immunodefic Rev. 1988; 1(1):39-54. View Abstract
  374. cDNA cloning and complete primary structure of the alpha subunit of a leukocyte adhesion glycoprotein, p150,95. EMBO J. 1987 Dec 20; 6(13):4023-8. View Abstract
  375. Purified intercellular adhesion molecule-1 (ICAM-1) is a ligand for lymphocyte function-associated antigen 1 (LFA-1). Cell. 1987 Dec 04; 51(5):813-9. View Abstract
  376. Purified lymphocyte function-associated antigen-3 and T11 target structure are active in CD2-mediated T cell stimulation. Eur J Immunol. 1987 Dec; 17(12):1847-50. View Abstract
  377. Leukocyte adhesion receptors are stored in peroxidase-negative granules of human neutrophils. J Exp Med. 1987 Dec 01; 166(6):1641-53. View Abstract
  378. Serologic cross-reactivity of T11 target structure and lymphocyte function-associated antigen 3. Evidence for structural homology of the sheep and human ligands of CD2. J Immunol. 1987 Oct 15; 139(8):2696-701. View Abstract
  379. Rosetting of human T lymphocytes with sheep and human erythrocytes. Comparison of human and sheep ligand binding using purified E receptor. J Immunol. 1987 Oct 15; 139(8):2690-5. View Abstract
  380. Monoclonal antibodies to CD2 and lymphocyte function-associated antigen 3 inhibit human thymic epithelial cell-dependent mature thymocyte activation. J Immunol. 1987 Oct 15; 139(8):2573-8. View Abstract
  381. Deficiency of lymphocyte function-associated antigen 3 (LFA-3) in paroxysmal nocturnal hemoglobinuria. Functional correlates and evidence for a phosphatidylinositol membrane anchor. J Exp Med. 1987 Oct 01; 166(4):1011-25. View Abstract
  382. Primary structure of lymphocyte function-associated antigen 3 (LFA-3). The ligand of the T lymphocyte CD2 glycoprotein. J Exp Med. 1987 Oct 01; 166(4):923-32. View Abstract
  383. Anchoring mechanisms for LFA-3 cell adhesion glycoprotein at membrane surface. Nature. 1987 Oct 29-Nov 4; 329(6142):846-8. View Abstract
  384. Chemoattractant-regulated mobilization of a novel intracellular compartment in human neutrophils. Science. 1987 Sep 04; 237(4819):1204-6. View Abstract
  385. Biosynthesis and glycosylation of p150,95 and related leukocyte adhesion proteins. J Immunol. 1987 Aug 01; 139(3):842-7. View Abstract
  386. Stimulated mobilization of monocyte Mac-1 and p150,95 adhesion proteins from an intracellular vesicular compartment to the cell surface. J Clin Invest. 1987 Aug; 80(2):535-44. View Abstract
  387. Heterogeneous mutations in the beta subunit common to the LFA-1, Mac-1, and p150,95 glycoproteins cause leukocyte adhesion deficiency. Cell. 1987 Jul 17; 50(2):193-202. View Abstract
  388. Polymorphism of lymphocyte function-associated antigen-1 demonstrated by a lupus patient's alloantiserum. J Clin Invest. 1987 Jun; 79(6):1607-14. View Abstract
  389. Activation of cultured human endothelial cells by recombinant lymphotoxin: comparison with tumor necrosis factor and interleukin 1 species. J Immunol. 1987 May 15; 138(10):3319-24. View Abstract
  390. Purification and alpha subunit N-terminal sequences of human Mac-1 and p150,95 leukocyte adhesion proteins. J Immunol. 1987 Apr 15; 138(8):2381-3. View Abstract
  391. Rosetting of activated human T lymphocytes with autologous erythrocytes. Definition of the receptor and ligand molecules as CD2 and lymphocyte function-associated antigen 3 (LFA-3). J Exp Med. 1987 Mar 01; 165(3):664-76. View Abstract
  392. Purified lymphocyte function-associated antigen 3 binds to CD2 and mediates T lymphocyte adhesion. J Exp Med. 1987 Mar 01; 165(3):677-92. View Abstract
  393. The T lymphocyte glycoprotein CD2 binds the cell surface ligand LFA-3. Nature. 1987 Mar 26-Apr 1; 326(6111):400-3. View Abstract
  394. Cloning of the beta subunit of the leukocyte adhesion proteins: homology to an extracellular matrix receptor defines a novel supergene family. Cell. 1987 Feb 27; 48(4):681-90. View Abstract
  395. Thymocyte binding to human thymic epithelial cells is inhibited by monoclonal antibodies to CD-2 and LFA-3 antigens. J Immunol. 1987 Jan 15; 138(2):358-63. View Abstract
  396. The lymphocyte function-associated LFA-1, CD2, and LFA-3 molecules: cell adhesion receptors of the immune system. Annu Rev Immunol. 1987; 5:223-52. View Abstract
  397. Leukocyte adhesion deficiency: an inherited defect in the Mac-1, LFA-1, and p150,95 glycoproteins. Annu Rev Med. 1987; 38:175-94. View Abstract
  398. Abnormal cytolytic activity of lymphocyte function-associated antigen-1-deficient human cytolytic T lymphocyte clones. J Clin Invest. 1986 Nov; 78(5):1387-91. View Abstract
  399. Regulated expression of the Mac-1, LFA-1, p150,95 glycoprotein family during leukocyte differentiation. J Immunol. 1986 Nov 01; 137(9):2891-900. View Abstract
  400. T lymphocyte adhesion to endothelial cells: mechanisms demonstrated by anti-LFA-1 monoclonal antibodies. J Immunol. 1986 Nov 01; 137(9):2901-6. View Abstract
  401. Overlapping patterns of activation of human endothelial cells by interleukin 1, tumor necrosis factor, and immune interferon. J Immunol. 1986 Sep 15; 137(6):1893-6. View Abstract
  402. Two antigen-independent adhesion pathways used by human cytotoxic T-cell clones. Nature. 1986 Sep 18-24; 323(6085):262-4. View Abstract
  403. LFA-1 immunodeficiency disease. Definition of the genetic defect and chromosomal mapping of alpha and beta subunits of the lymphocyte function-associated antigen 1 (LFA-1) by complementation in hybrid cells. J Exp Med. 1986 Sep 01; 164(3):855-67. View Abstract
  404. A human intercellular adhesion molecule (ICAM-1) distinct from LFA-1. J Immunol. 1986 Aug 15; 137(4):1270-4. View Abstract
  405. The mouse leukocyte adhesion proteins Mac-1 and LFA-1: studies on mRNA translation and protein glycosylation with emphasis on Mac-1. J Immunol. 1986 Aug 01; 137(3):1060-5. View Abstract
  406. A partial genomic DNA clone for the alpha subunit of the mouse complement receptor type 3 and cellular adhesion molecule Mac-1. Proc Natl Acad Sci U S A. 1986 Aug; 83(15):5644-8. View Abstract
  407. Differentiation of myeloid cells is accompanied by increased levels of pp60c-src protein and kinase activity. Proc Natl Acad Sci U S A. 1986 Jul; 83(14):5131-5. View Abstract
  408. Contributions of the Mac-1 glycoprotein family to adherence-dependent granulocyte functions: structure-function assessments employing subunit-specific monoclonal antibodies. J Immunol. 1986 Jul 01; 137(1):15-27. View Abstract
  409. Purification and characterization of the lymphocyte function-associated-2 (LFA-2) molecule. J Immunol. 1986 Jun 01; 136(11):4181-7. View Abstract
  410. Mechanisms of tumor cell capture by activated macrophages: evidence for involvement of lymphocyte function-associated (LFA)-1 antigen. J Immunol. 1986 Jun 01; 136(11):4328-33. View Abstract
  411. The requirement for lymphocyte function-associated antigen 1 in homotypic leukocyte adhesion stimulated by phorbol ester. J Exp Med. 1986 May 01; 163(5):1132-49. View Abstract
  412. Interaction of West Nile virus with primary murine macrophages: role of cell activation and receptors for antibody and complement. J Virol. 1986 Mar; 57(3):952-9. View Abstract
  413. Defective membrane expression of the LFA-1 complex may be secondary to the absence of the beta chain in a child with recurrent bacterial infection. Eur J Immunol. 1986 Feb; 16(2):205-8. View Abstract
  414. The importance of the Mac-1, LFA-1 glycoprotein family in monocyte and granulocyte adherence, chemotaxis, and migration into inflammatory sites: insights from an experiment of nature. Ciba Found Symp. 1986; 118:102-26. View Abstract
  415. p150,95, the third member of the Mac-1, LFA-1 human leukocyte adhesion glycoprotein family. J Immunol. 1986 Jan; 136(1):240-5. View Abstract
  416. Production of Syrian and Armenian hamster monoclonal antibodies of defined specificity. Methods Enzymol. 1986; 121:239-44. View Abstract
  417. Leukocyte complement receptors and adhesion proteins in the inflammatory response: insights from an experiment of nature. Biochem Soc Symp. 1986; 51:47-57. View Abstract
  418. Biochemical models of interferon-gamma-mediated macrophage activation: independent regulation of lymphocyte function associated antigen (LFA)-1 and I-A antigen on murine peritoneal macrophages. Cell Immunol. 1986 Jan; 97(1):110-20. View Abstract
  419. Deficiency of the adhesive protein complex lymphocyte function antigen 1, complement receptor type 3, glycoprotein p150,95 in a girl with recurrent bacterial infections. Effects on phagocytic cells and lymphocyte functions. J Clin Invest. 1985 Dec; 76(6):2385-92. View Abstract
  420. Heritable lymphocyte function-associated antigen-1 deficiency: abnormalities of cytotoxicity and proliferation associated with abnormal expression of LFA-1. J Immunol. 1985 Nov; 135(5):3102-8. View Abstract
  421. Complement receptor type three-dependent degradation of opsonized erythrocytes by mouse macrophages. J Immunol. 1985 Oct; 135(4):2668-72. View Abstract
  422. Characterization of patients with an increased susceptibility to bacterial infections and a genetic deficiency of leukocyte membrane complement receptor type 3 and the related membrane antigen LFA-1. Blood. 1985 Oct; 66(4):882-90. View Abstract
  423. The severe and moderate phenotypes of heritable Mac-1, LFA-1 deficiency: their quantitative definition and relation to leukocyte dysfunction and clinical features. J Infect Dis. 1985 Oct; 152(4):668-89. View Abstract
  424. Antigens associated with the activation of murine mononuclear phagocytes in vivo: differential expression of lymphocyte function-associated antigen in the several stages of development. Cell Immunol. 1985 Aug; 94(1):265-75. View Abstract
  425. The LFA-1, Mac-1 glycoprotein family and its deficiency in an inherited disease. Fed Proc. 1985 Jul; 44(10):2660-3. View Abstract
  426. Leukocyte LFA-1, OKM1, p150,95 deficiency syndrome: functional and biosynthetic studies of three kindreds. Fed Proc. 1985 Jul; 44(10):2671-7. View Abstract
  427. Studies on antigens associated with the activation of murine mononuclear phagocytes: kinetics of and requirements for induction of lymphocyte function-associated (LFA)-1 antigen in vitro. J Immunol. 1985 Jul; 135(1):147-51. View Abstract
  428. Characterization of a monoclonal rat anti-mouse interleukin 2 (IL-2) receptor antibody and its use in the biochemical characterization of the murine IL-2 receptor. Clin Immunol Immunopathol. 1985 Jul; 36(1):18-29. View Abstract
  429. Identification of cell surface antigens present on murine hematopoietic stem cells. J Immunol. 1985 May; 134(5):3286-90. View Abstract
  430. Susceptibility of cytotoxic T lymphocyte (CTL) clones to inhibition by anti-T3 and anti-T4 (but not anti-LFA-1) monoclonal antibodies varies with the "avidity" of CTL-target interaction. J Immunol. 1985 May; 134(5):3019-26. View Abstract
  431. Sequence homology of the LFA-1 and Mac-1 leukocyte adhesion glycoproteins and unexpected relation to leukocyte interferon. Nature. 1985 Apr 11-17; 314(6011):540-2. View Abstract
  432. The function of LFA-1 in cell-mediated killing and adhesion: studies on heritable LFA-1, Mac-1 deficiency and on lymphoid cell self-aggregation. Adv Exp Med Biol. 1985; 184:311-22. View Abstract
  433. The Ly-15 alloantigenic system: a genetically determined polymorphism of the murine lymphocyte function-associated antigen-1 molecule. Proc Natl Acad Sci U S A. 1985 Jan; 82(2):526-30. View Abstract
  434. Defective natural killer cytotoxicity and polymorphonuclear leukocyte antibody-dependent cellular cytotoxicity in patients with LFA-1/OKM-1 deficiency. J Immunol. 1984 Dec; 133(6):2972-8. View Abstract
  435. Inherited deficiency of the Mac-1, LFA-1, p150,95 glycoprotein family and its molecular basis. J Exp Med. 1984 Dec 01; 160(6):1901-18. View Abstract
  436. Abnormalities of polymorphonuclear leukocyte function associated with a heritable deficiency of high molecular weight surface glycoproteins (GP138): common relationship to diminished cell adherence. J Clin Invest. 1984 Aug; 74(2):536-51. View Abstract
  437. Glycoproteins of 210,000 and 130,000 m.w. on activated T cells: cell distribution and antigenic relation to components on resting cells and T cell lines. J Immunol. 1984 Jun; 132(6):3011-8. View Abstract
  438. LFA-1, LFA-2, and LFA-3 antigens are involved in CTL-target conjugation. J Immunol. 1984 May; 132(5):2180-2. View Abstract
  439. Preparation and use of monoclonal antimacrophage antibodies. Methods Enzymol. 1984; 108:313-24. View Abstract
  440. Deficiency of a surface membrane glycoprotein (Mo1) in man. J Clin Invest. 1984 Jan; 73(1):153-9. View Abstract
  441. Human lymphocyte function-associated antigens. Surv Immunol Res. 1984; 3(1):39-44. View Abstract
  442. Analysis of macrophage differentiation and function with monoclonal antibodies. Contemp Top Immunobiol. 1984; 13:1-31. View Abstract
  443. Lymphokine inducing "terminal differentiation" of the human monoblast leukemia line U937: a role for gamma interferon. Blood. 1983 Dec; 62(6):1169-75. View Abstract
  444. A human leukocyte differentiation antigen family with distinct alpha-subunits and a common beta-subunit: the lymphocyte function-associated antigen (LFA-1), the C3bi complement receptor (OKM1/Mac-1), and the p150,95 molecule. J Exp Med. 1983 Dec 01; 158(6):1785-1803. View Abstract
  445. Human lymphocyte function associated antigen-1 (LFA-1): identification of multiple antigenic epitopes and their relationship to CTL-mediated cytotoxicity. J Immunol. 1983 Sep; 131(3):1182-8. View Abstract
  446. Mapping of antigenic and functional epitopes on the alpha- and beta-subunits of two related mouse glycoproteins involved in cell interactions, LFA-1 and Mac-1. J Exp Med. 1983 Aug 01; 158(2):586-602. View Abstract
  447. The functional significance, distribution, and structure of LFA-1, LFA-2, and LFA-3: cell surface antigens associated with CTL-target interactions. J Immunol. 1983 Aug; 131(2):611-6. View Abstract
  448. Monoclonal antibodies against rat glomerular antigens: production and specificity. Lab Invest. 1983 Jul; 49(1):107-17. View Abstract
  449. Blocking of CTL-mediated killing by monoclonal antibodies to LFA-1 and LYT-2,3. I. Increased susceptibility to blocking after papain treatment of target cells. J Immunol. 1983 Jun; 130(6):2546-51. View Abstract
  450. Staining of Langerhans cells with monoclonal antibodies to macrophages and lymphoid cells. Proc Natl Acad Sci U S A. 1983 Jun; 80(11):3448-51. View Abstract
  451. Dendritic cell and macrophage staining by monoclonal antibodies in tissue sections and epidermal sheets. Am J Pathol. 1983 Apr; 111(1):112-24. View Abstract
  452. Biosynthesis and assembly of the alpha and beta subunits of Mac-1, a macrophage glycoprotein associated with complement receptor function. J Biol Chem. 1983 Mar 10; 258(5):2766-9. View Abstract
  453. All monocyte antigens are not expressed on renal endothelium. Tissue Antigens. 1983 Mar; 21(3):254-9. View Abstract
  454. Tissue distribution, structural characterization, and biosynthesis of Mac-3, a macrophage surface glycoprotein exhibiting molecular weight heterogeneity. J Biol Chem. 1983 Jan 10; 258(1):636-42. View Abstract
  455. Cytotoxic T cells directed against HLA-DR antigens and their surface proteins. Diagn Immunol. 1983; 1(3):116-9. View Abstract
  456. Quantitation of hybridoma immunoglobulins and selection of light-chain loss variants. Methods Enzymol. 1983; 92:147-60. View Abstract
  457. Expression and induction in vitro of macrophage differentiation antigens on murine cell lines. J Immunol. 1983 Jan; 130(1):108-14. View Abstract
  458. Stable hamster-mouse hybridomas producing IgG and IgM hamster monoclonal antibodies of defined specificity. J Immunol. 1983 Jan; 130(1):309-12. View Abstract
  459. Three distinct antigens associated with human T-lymphocyte-mediated cytolysis: LFA-1, LFA-2, and LFA-3. Proc Natl Acad Sci U S A. 1982 Dec; 79(23):7489-93. View Abstract
  460. LFA-1 but not Lyt-2 is associated with killing activity of cytotoxic T lymphocyte hybridomas. Nature. 1982 Nov 25; 300(5890):357-60. View Abstract
  461. Purification and structural characterization of LFA-1, a lymphocyte function-associated antigen, and Mac-1, a related macrophage differentiation antigen associated with the type three complement receptor. J Biol Chem. 1982 Oct 25; 257(20):12412-8. View Abstract
  462. Antigens involved in mouse cytolytic T-lymphocyte (CTL)-mediated killing: functional screening and topographic relationship. Cell Immunol. 1982 Oct; 73(1):1-11. View Abstract
  463. Anti-Mac-1 selectively inhibits the mouse and human type three complement receptor. J Exp Med. 1982 Oct 01; 156(4):1000-9. View Abstract
  464. Role of syngeneic Ia+ accessory cells in the generation of allospecific CTL responses. J Immunol. 1982 Aug; 129(2):694-7. View Abstract
  465. Mac-1 antigen: quantitative expression in macrophage populations and tissues, and immunofluorescent localization in spleen. J Immunol. 1982 May; 128(5):2281-6. View Abstract
  466. Structural homology of a macrophage differentiation antigen and an antigen involved in T-cell-mediated killing. Nature. 1982 Apr 15; 296(5858):668-70. View Abstract
  467. Mac-2, a novel 32,000 Mr mouse macrophage subpopulation-specific antigen defined by monoclonal antibodies. J Immunol. 1982 Mar; 128(3):1221-8. View Abstract
  468. A single monoclonal anti-Ia antibody inhibits antigen-specific T cell proliferation controlled by distinct Ir genes mapping in different H-2 I subregions. J Immunol. 1982 Mar; 128(3):1409-13. View Abstract
  469. LFA-1 and Lyt-2,3, molecules associated with T lymphocyte-mediated killing; and Mac-1, an LFA-1 homologue associated with complement receptor function. Immunol Rev. 1982; 68:171-95. View Abstract
  470. Monoclonal antibodies specific for rat IgG1, IgG2a, and IgG2b subclasses, and kappa chain monotypic and allotypic determinants: reagents for use with rat monoclonal antibodies. Hybridoma. 1982; 1(3):257-73. View Abstract
  471. The molecular basis for cytolytic T lymphocyte function: analysis with blocking monoclonal antibodies. Adv Exp Med Biol. 1982; 146:447-68. View Abstract
  472. A shared alloantigenic determinant on Ia antigens encoded by the I-A and I-E subregions: evidence for I region gene duplication. J Immunol. 1981 Dec; 127(6):2488-95. View Abstract
  473. Natural killer activity in the peritoneal exudates of mice infected with Listeria monocytogenes: characterization of the natural killer cells by using a monoclonal rat anti-murine macrophage antibody (M1/70). J Immunol. 1981 Nov; 127(5):1792-9. View Abstract
  474. Characterization of an anti-H-2 monoclonal antibody and its use in large-scale antigen purification. J Immunol. 1981 Sep; 127(3):923-30. View Abstract
  475. Monoclonal antibody to a novel lymphocyte function-associated antigen (LFA-1): mechanism of blockade of T lymphocyte-mediated killing and effects on other T and B lymphocyte functions. J Immunol. 1981 Aug; 127(2):590-5. View Abstract
  476. A novel lymphocyte function-associated antigen (LFA-1): cellular distribution, quantitative expression, and structure. J Immunol. 1981 Aug; 127(2):596-602. View Abstract
  477. Lymphocyte function-associated antigen 1 (LFA-1): a surface antigen distinct from Lyt-2,3 that participates in T lymphocyte-mediated killing. Proc Natl Acad Sci U S A. 1981 Jul; 78(7):4535-9. View Abstract
  478. Monoclonal antibody analysis of complex biological systems. Combination of cell hybridization and immunoadsorbents in a novel cascade procedure and its application to the macrophage cell surface. J Biol Chem. 1981 Apr 25; 256(8):3833-9. View Abstract
  479. Use of a monoclonal antibody specifically non-reactive with T cells to delineate lymphocyte subpopulations. Immunology. 1981 Mar; 42(3):371-8. View Abstract
  480. Cross-reaction of a rat-anti-mouse phagocyte-specific monoclonal antibody (anti-Mac-1) with human monocytes and natural killer cells. J Immunol. 1981 Jan; 126(1):359-64. View Abstract
  481. Quantitation of light chain synthesis in myeloma x spleen cell hybrids and identification of myeloma chain loss variants using radioimmunoassay. J Immunol Methods. 1980; 37(2):139-52. View Abstract
  482. Mac-1: a macrophage differentiation antigen identified by monoclonal antibody. Eur J Immunol. 1979 Apr; 9(4):301-6. View Abstract
  483. Monoclonal antibodies and cell surface antigens. Cell Biol Int Rep. 1979 Jan; 3(1):1-16. View Abstract
  484. Monoclonal xenogeneic antibodies to murine cell surface antigens: identification of novel leukocyte differentiation antigens. Eur J Immunol. 1978 Aug; 8(8):539-51. View Abstract
  485. Monoclonal antibodies as probes for differentiation and tumor-associated antigens: a Forssman specificity on teratocarcinoma stem cells. Cell. 1978 Aug; 14(4):775-83. View Abstract
  486. Monoclonal xenogeneic antibodies to mouse leukocyte antigens: identification of macrophage-specific and other differentiation antigens. Curr Top Microbiol Immunol. 1978; 81:45-50. View Abstract
  487. Purification of HLA-linked B lymphocyte alloantigens in immunologically active form by preparative sodium dodecyl sulfate-gel electrophoresis and studies on their subunit association. J Biol Chem. 1977 Sep 10; 252(17):6201-7. View Abstract
  488. Purification and structural characterisation of human HLA-linked B-cell antigens. Nature. 1977 Jul 21; 268(5617):213-8. View Abstract
  489. Detergent solubilization, purification, and separation of specificities of HLA antigens from a cultured human lymphoblastoid line, RPMI 4265. J Biol Chem. 1977 Jul 10; 252(13):4682-93. View Abstract
  490. Submit and disulfide structure of monomeric and dimeric forms of detergent-soluble HLA antigens. J Biol Chem. 1977 Jul 10; 252(13):4694-700. View Abstract
  491. Detergent-soluble products of the HLA region. Transplant Proc. 1977 Mar; 9(1 Suppl 1):21-8. View Abstract
  492. Chemical and immunological characterization of HL-A linked B-lymphocyte alloantigens. Cold Spring Harb Symp Quant Biol. 1977; 41 Pt 1:387-96. View Abstract
  493. Structure of HL-A A and B antigens isolated from cultured human lymphocytes. Cold Spring Harb Symp Quant Biol. 1977; 41 Pt 1:323-9. View Abstract
  494. Detergent-soluble HLA antigens contain a hydrophilic region at the COOH-terminus and a penultimate hydrophobic region. Proc Natl Acad Sci U S A. 1976 Jul; 73(7):2481-5. View Abstract
  495. The immunoglobulin-like structure of human histocompatibility antigens. Fed Proc. 1976 Apr; 35(5):1177-82. View Abstract
  496. Immunological identity of the small subunit of HL-A antigens and beta2-microglobulin and its turnover on the cell membrane. Proc Natl Acad Sci U S A. 1974 May; 71(5):2123-7. View Abstract
  497. Partial purification of detergent-soluble HL-A antigen and its cleavage by papain. Proc Natl Acad Sci U S A. 1974 Apr; 71(4):1539-43. View Abstract
  498. The immunoglobulin-like structure of human histocompatibility antigens. Transplant Rev. 1974; 21(0):126-43. View Abstract
  499. The small subunit of HL-A antigens is beta 2-microglobulin. J Exp Med. 1973 Dec 01; 138(6):1608-12. View Abstract

Contact Timothy A. Springer

Print Profile